

Reference:	FOI.17439.25
Subject:	Medications
Date of Request:	29 May 2025

Requested:

1. In the last 12 months, how many unique patients in your health board were treated with the following products:
 - a. Curosurf
 - b. Peyona

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The UHB does not keep a central record of patients that received the medications listed, they are recorded as the number of packs dispensed as ward stock. Therefore, in order to provide you with the requested data, the UHB would need to undertake a manual trawl of maternity patient records, to identify any information that would fulfil your request.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB confirms that one hundred and sixteen (116) packs of the medication Curosurf (Poractant Alfa) were issued as ward stock and no packs of Peyona (Caffiene citrate) were issued, during the period 1 May to 30 April 2025.